SeaSun Biomaterials, a molecular diagnostic company, participated in the 71st ``American Society of Clinical Chemistry Clinical Chemistry Experimental Equipment and Medical Diagnosis Expo'' held in Anaheim, California, USA for 5 days from the 4th to consulting with over 100 foreign companies It was revealed on the 14th.

The AACC Expo is an academic conference attended by more than 20,000 specialists in diagnostic laboratory medicine, pathology, and radiology every year, as well as the world's largest in vitro diagnostic exhibition. This year, 879 companies from 29 countries participated. As for Korean companies, 33 companies such as Sisun Bio were exhibiting.

With the slogan of'Innovation in Diagnosis and Health Management', SeaSun Biomaterials has exhibited and promoted prenatal fetal malformation tests, newborn congenital hearing loss screening tests, and screening products for early cancer diagnosis, which are essential for full-cycle health management from fetus to adult.

For products using real time PCR, the results can be confirmed within 2 to 4 hours with a simple preparation process and analysis. Non-invasive prenatal fetal genetic testing (NIPT) using mother's blood can be analyzed in 4 hours, so when you request the prenatal testing service'Mom's Eyes', you can receive a report of the reading result within 3 days (about 7 days of the existing product). It is the fastest among NIPT tests and boasts over 99% accuracy.

This year's highlight exhibition item is DNA methylation analysis technology that does not require pretreatment with sodium bisulfite. Existing test methods for screening cancer-causing mutations have a limitation in that they can produce diagnostic results only after repeated tests several times due to low reproducibility according to bisulfite reaction. On the other hand, the new technology of SeaSun Biomaterials received high praise in that it solved this hassle.

The upgraded microsatellite instability (MSI) test was well received by reproducing the same results in blood, not tissues. This product (U-TOP MSI Detection Kit) was introduced at the AACC Expo held last year as the world's first product for determining microsatellite instability using real-time PCR.

It is an essential test kit to determine MSI-H (high frequency microsatellite instability), which is a reference standard when customizing the immune anticancer drug 'Kitruda' (ingredient name pembrolizumab) from Merck (MSD) in the United States. This is increasing.

"DNA methylation analysis technology, microsatellite instability blood test, real-time PCR method of prenatal fetal genetic test, etc. are meaningful in developing their own technology in areas where even leading global companies have not challenged." As we secured technology and introduced only products that were certified in Korea and Europe, the reliability of the participating companies was very high.” He said, "AACC Expo is a place to establish a sales network for product promotion, technology verification, and overseas market development," he said. "Over 100 molecular diagnostic companies including Brazil, Canada, Costa Rica, etc. Among them, Thai and Uruguay companies have expressed their intention to introduce products.”